SML2156

Erlotinib hydrochloride

≥98% (HPLC), EGFR kinase inhibitor, powder

• Sinónimos: 774 hydrochloride, CP-358, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, OSI-744 hydrochloride
• Fórmula empírica (notación de Hill): C₂₂H₂₃N₃O₄ · HCl
• Número CAS: 183319-69-9
• Peso molecular: 429.90
• UNSPSC Code: 12352200
• NACRES: NA.77
• MDL number: MFCD07781272
• Assay: ≥98% (HPLC)
• Form: powder
• Storage condition: desiccated

Propiedades

• Nombre del producto: Erlotinib hydrochloride, ≥98% (HPLC)
• assay: ≥98% (HPLC)
• form: powder
• storage condition: desiccated
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear (warmed)
• storage temp.: −20°C
• SMILES string: Cl.N(c3cc(ccc3)C#C)c1ncnc2c1cc(c(c2)OCCOC)OCCOC
• InChI: 1S/C22H23N3O4.ClH/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22;/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25);1H
• InChI key: GTTBEUCJPZQMDZ-UHFFFAOYSA-N

Descripción

General description

Erlotinib hydrochloride is an antineoplastic drug. It regulates mechanistic target of rapamycin (mTOR) inhibition, epidermal growth factor receptor down-regulation and epidermal interstitial transformation (EMT) suppression.

Application

Erlotinib hydrochloride has been used to activate mitochondrial fragmentation in a human PANC-1 pancreatic cancer cell line.

Biochem/physiol Actions

EGFR kinase inhibitor; Antineoplastic

Erlotinib hydrochloride is an inhibitor of the receptor tyrosine kinase EGFR (epidermal growth factor receptor). It is used clinically for the treatment of non-small cell lung cancer (NSCLC) and in combination for metastatic pancreatic cancer.

Información de seguridad

• pictograms: GHS07
• signalword: Warning
• hcodes: H302
• pcodes: P264 - P270 - P301 + P312 - P501
• Hazard Classifications: Acute Tox. 4 Oral
• Clase de almacenamiento: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable